

Richard E Clark

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2999092/publications.pdf>

Version: 2024-02-01

116
papers

7,481
citations

147566

31
h-index

54797

84
g-index

119
all docs

119
docs citations

119
times ranked

6378
citing authors

#	ARTICLE	IF	CITATIONS
1	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
2	Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 362, 2251-2259.	13.9	1,497
3	Active transport of imatinib into and out of cells: implications for drug resistance. <i>Blood</i> , 2004, 104, 3739-3745.	0.6	598
4	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1295-1305.	5.1	433
5	Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. <i>Blood</i> , 2001, 98, 2887-2893.	0.6	231
6	A randomized comparison of daunorubicin 90 mg/m ² vs 60 mg/m ² in AML induction: results from the UK NCRI AML17 trial in 1206 patients. <i>Blood</i> , 2015, 125, 3878-3885.	0.6	230
7	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 612-621.	5.1	214
8	hOCT 1 and resistance to imatinib. <i>Blood</i> , 2005, 106, 1133-1134.	0.6	196
9	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. <i>Leukemia</i> , 2021, 35, 440-453.	3.3	159
10	The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 990-999.	1.2	133
11	De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. <i>Lancet Haematology</i> , the, 2019, 6, e375-e383.	2.2	129
12	Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. <i>Blood</i> , 2008, 112, 3348-3354.	0.6	115
13	De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. <i>Lancet Haematology</i> , the, 2017, 4, e310-e316.	2.2	97
14	Response to ruxolitinib in patients with intermediate ¹ , intermediate ² , and high ³ risk myelofibrosis: results of the <sc>UK ROBUST</sc> Trial. <i>British Journal of Haematology</i> , 2015, 170, 29-39.	1.2	82
15	Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. <i>Journal of the National Cancer Institute</i> , 2018, 110, 467-478.	3.0	76
16	An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1351-1358.	1.7	70
17	Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m ² with 6 mg/m ² in the NCRI AML17 Trial. <i>Haematologica</i> , 2016, 101, 724-731.	1.7	60
18	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2138-2149.	3.3	55

#	ARTICLE	IF	CITATIONS
19	Successful Outcome of Pregnancy in Chronic Myeloid Leukaemia Treated with Imatinib. <i>Leukemia and Lymphoma</i> , 2004, 45, 1307-1308.	0.6	54
20	Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. <i>Leukemia Research</i> , 2010, 34, 702-707.	0.4	49
21	The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. <i>Haematologica</i> , 2006, 91, 235-9.	1.7	48
22	Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2923-2932.	0.6	46
23	CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. <i>Leukemia</i> , 2020, 34, 1613-1625.	3.3	46
24	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. <i>Leukemia</i> , 2022, 36, 1825-1833.	3.3	43
25	E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2017, 102, e297-e299.	1.7	42
26	Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. <i>Blood</i> , 2014, 124, 4541-4541.	0.6	42
27	b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2000, 109, 616-621.	1.2	41
28	Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. <i>Blood</i> , 2000, 96, 2697-2702.	0.6	40
29	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor- Sensitive and -Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2289-2300.	3.2	38
30	Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. <i>Haematologica</i> , 2005, 90, 1315-23.	1.7	37
31	ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes. <i>Blood</i> , 2013, 122, 92-92.	0.6	34
32	Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). <i>Blood</i> , 2014, 124, 519-519.	0.6	30
33	EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. <i>Blood</i> , 2010, 116, 6014-6017.	0.6	29
34	Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. <i>Blood</i> , 2020, 136, 41-42.	0.6	27
35	Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. <i>Blood Advances</i> , 2021, 5, 1102-1109.	2.5	25
36	AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial. <i>Blood</i> , 2013, 122, 622-622.	0.6	24

#	ARTICLE	IF	CITATIONS
37	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 639-642.	0.6	22
38	Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 507-514.	1.2	22
39	Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. <i>Blood</i> , 2019, 134, 2924-2924.	0.6	22
40	Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2012, 120, 1676-1676.	0.6	21
41	ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7073-7073.	0.8	21
42	Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2022, 9, e121-e132.	2.2	21
43	Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML. <i>Blood</i> , 2020, 135, 766-769.	0.6	20
44	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. <i>Journal of Clinical Oncology</i> , 2021, 39, 890-901.	0.8	20
45	Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial. <i>Blood</i> , 2009, 114, LBA-1-LBA-1.	0.6	20
46	Poor Cellular Uptake of Antisense Oligodeoxynucleotides: An Obstacle to their Use in Chronic Myeloid Leukaemia. <i>Leukemia and Lymphoma</i> , 1995, 19, 189-195.	0.6	18
47	Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. <i>Experimental Hematology</i> , 2012, 40, 811-819.e2.	0.2	18
48	Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. <i>British Journal of Haematology</i> , 2021, 192, 62-74.	1.2	18
49	FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/III UK Trials Acceleration Programme Matchpoint Trial. <i>Blood</i> , 2019, 134, 497-497.	0.6	18
50	Spirit 2: An NCR1 Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML. <i>Blood</i> , 2014, 124, 517-517.	0.6	18
51	Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCR1 acute myeloid leukemia 16 trial. <i>Haematologica</i> , 2022, 107, 1518-1527.	1.7	18
52	HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 2001, 114, 36-41.	1.2	17
53	BCR-ABL Fusion Peptides and Cytotoxic T Cells in Chronic Myeloid Leukaemia. <i>Leukemia and Lymphoma</i> , 2001, 42, 871-880.	0.6	17
54	Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. <i>American Journal of Hematology</i> , 2019, 94, 1236-1243.	2.0	17

#	ARTICLE	IF	CITATIONS
55	CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. <i>Blood Advances</i> , 2018, 2, 964-968.	2.5	15
56	Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. <i>Haematologica</i> , 2018, 103, 1654-1661.	1.7	14
57	BCR-ABL peptide vaccination in healthy subjects: Immunological responses are equivalent to those in chronic myeloid leukaemia patients. <i>Leukemia Research</i> , 2011, 35, 369-372.	0.4	13
58	A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. <i>Leukemia Research</i> , 2013, 37, 752-758.	0.4	13
59	Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. <i>Haematologica</i> , 2014, 99, 1710-1715.	1.7	13
60	Evidence that the pregnane X and retinoid receptors PXR , RAR and RXR may regulate transcription of the transporter $OCT1$ in chronic myeloid leukaemia cells. <i>European Journal of Haematology</i> , 2015, 94, 74-78.	1.1	13
61	Evaluating the use of plerixafor in stem cell mobilisation – an economic analysis of the $PHANTASTIC$ trial. <i>Journal of Clinical Apheresis</i> , 2016, 31, 434-442.	0.7	13
62	Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. <i>Leukemia</i> , 2019, 33, 1810-1814.	3.3	13
63	Severe hypophosphataemia during stem cell harvesting in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1995, 90, 450-452.	1.2	12
64	Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. <i>Blood Advances</i> , 2016, 1, 160-169.	2.5	12
65	Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. <i>Clinical Cancer Research</i> , 2021, 27, 2848-2860.	3.2	11
66	Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. <i>Blood Advances</i> , 2021, 5, 5621-5625.	2.5	11
67	Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. <i>Blood</i> , 2018, 132, 457-457.	0.6	10
68	Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials. <i>Blood</i> , 2013, 122, 358-358.	0.6	9
69	Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia. <i>Leukemia Research</i> , 2009, 33, 1151-1155.	0.4	8
70	Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2019, 134, 26-26.	0.6	8
71	Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia. , 1997, 18, 292-298.		7
72	Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd. , <i>Blood</i> , 2011, 118, 3768-3768.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Bone Turnover Following Autologous Transplantation in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2002, 43, 511-516.	0.6	6
74	Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells. <i>Biochemical Journal</i> , 2019, 476, 2255-2269.	1.7	6
75	The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial. <i>British Journal of Haematology</i> , 2019, 185, 791-793.	1.2	6
76	A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. <i>British Journal of Haematology</i> , 2021, 194, 298-308.	1.2	6
77	Transplantation of t-lymphocyte depleted marrow with an addback of T cells. <i>Hematological Oncology</i> , 1995, 13, 219-224.	0.8	5
78	CMV-IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT. <i>Blood</i> , 2014, 124, 1109-1109.	0.6	5
79	Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study. <i>Blood</i> , 2016, 128, 938-938.	0.6	5
80	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7052-7052.	0.8	5
81	Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients. <i>Scientific Reports</i> , 2020, 10, 8394.	1.6	5
82	The chronic myeloid leukaemia story in the United Kingdom since 1960. <i>British Journal of Haematology</i> , 2020, 191, 521-526.	1.2	5
83	Long-Term Bone Marrow Cultures Established from Bone Marrow Transplant Recipients. <i>Leukemia and Lymphoma</i> , 1993, 12, 117-122.	0.6	4
84	Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. <i>Cancers</i> , 2021, 13, 2155.	1.7	4
85	A Randomised Comparison of Daunorubicin 90mg/m2 Vs 60mg/m2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients. <i>Blood</i> , 2014, 124, 7-7.	0.6	4
86	A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. <i>European Journal of Haematology</i> , 2022, 109, 90-99.	1.1	4
87	Identification of a Good C-MYC Antisense Oligodeoxynucleotide Target Site and the Inactivity at This Site of Novel NCH Triplet-Targeting Ribozymes. <i>Nucleosides & Nucleotides</i> , 1999, 18, 1935-1944.	0.5	3
88	Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib. <i>Blood</i> , 2011, 118, 1680-1680.	0.6	3
89	The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy. <i>Blood</i> , 2011, 118, 785-785.	0.6	3
90	A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience. <i>Blood</i> , 2014, 124, 3736-3736.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro. <i>Leukemia Research</i> , 2007, 31, 1675-1681.	0.4	2
92	Immunotherapeutic strategies in chronic myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 89-94.	1.2	2
93	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. <i>Leukemia and Lymphoma</i> , 2020, 61, 3287-3305.	0.6	2
94	Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent. <i>Blood</i> , 2013, 122, 93-93.	0.6	2
95	A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. <i>Blood</i> , 2014, 124, 2308-2308.	0.6	2
96	Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials. <i>Blood</i> , 2014, 124, 3160-3160.	0.6	2
97	Frequency of Blast Crisis after Achieving Complete Cytogenetic Remission in First Chronic Phase CML Patients Who Recieved Imatinib Therapy within Six Months of Diagnosis.. <i>Blood</i> , 2004, 104, 1021-1021.	0.6	2
98	Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data. <i>Blood</i> , 2014, 124, 3145-3145.	0.6	2
99	Another set of guidelines for chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 147-149.	1.2	1
100	Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia. , 1997, 18, 292.		1
101	CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. <i>Blood</i> , 2013, 122, 2735-2735.	0.6	1
102	Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry. <i>Blood</i> , 2015, 126, 2780-2780.	0.6	1
103	Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7051-7051.	0.8	1
104	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. <i>Blood</i> , 2014, 124, 4512-4512.	0.6	1
105	The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
106	T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies. <i>Blood</i> , 2008, 112, 4413-4413.	0.6	0
107	Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML.. <i>Blood</i> , 2009, 114, 42-42.	0.6	0
108	KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. <i>Blood</i> , 2010, 116, 888-888.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.. Blood, 2010, 116, 3397-3397.	0.6	0
110	Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP). Blood, 2013, 122, 4640-4640.	0.6	0
111	Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia. Blood, 2013, 122, 1469-1469.	0.6	0
112	A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia. Blood, 2014, 124, 3747-3747.	0.6	0
113	Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML. Blood, 2014, 124, 3489-3489.	0.6	0
114	PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia. Blood, 2015, 126, 1396-1396.	0.6	0
115	BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. Blood, 2015, 126, 1569-1569.	0.6	0
116	A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology, 2022, , .	1.2	0